Key Highlights
- This expansion is centered on two primary product candidates: AKB-097, a next-generation complement inhibitor, and praliciguat, a soluble guanylate cyclase/sGC stimulator.
- The development aligns with Akebia’s two-pronged corporate strategy: establishing Vafseo (vadadustat) as the standard of care for anemia in dialysis patients while building a robust pipeline for rare kidney conditions.
- Vafseo is an oral once-daily treatment for anemia due to chronic kidney disease/CKD in adults on dialysis for at least 3 months and is not indicated as a substitute for emergency blood transfusions.
- Vafseo is currently approved in 37 countries and works by stimulating endogenous production of erythropoietin.
- It carries a Boxed Warning regarding increased risks of death, myocardial infarction, stroke, and vascular thrombosis.
